

Freedom of Information Act 2000 - Request Reference FoI/22/398

Melanoma

Information Requested:

1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
 - Bevacizumab (Avastin)
 - Dacarbazine (DTIC)
 - Trametinib (Mekinist)
 - Dabrafenib (Tafinlar)
 - Ipilimumab (Yervoy)
 - Vemurafenib (Zelboraf)
 - Nivolumab (Opdivo)
 - Nivolumab + Ipilimumab (Opdivo + Yervoy)
 - Pembrolizumab (Keytruda)
 - Vemurafenib + cobimetinib (Zelboraf + Cotellic)
 - Dabrafenib + Trametinib (Tafinlar + Mekinist)
 - Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
 - Other active systemic anti-cancer therapy [please state]
 - Palliative care only
2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
 - Ipilimumab
 - Ipilimumab AND Nivolumab
 - Nivolumab
 - Pembrolizumab
 - Dabrafenib AND Trametinib
 - Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
 - Other active systemic anti-cancer therapy
 - Palliative care only

Response details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these treatments are provided by Velindre Cancer Centre, please see their contact details below:

foi.vunhst@wales.nhs.uk Or,

Velindre NHS Trust Headquarters.
Unit 2 Charnwood Court,
Parc Nantgarw,
Nantgarw,
Cardiff.
CF15 7QZ